Dyadic International, Inc. announced it has been awarded a $3 million grant from the Gates Foundation. This funding is designated for the cell line development of monoclonal antibodies (mAbs) targeting respiratory syncytial virus (RSV) and malaria.
The project will utilize the company’s proprietary C1 protein production platform. The initiative aims to develop globally accessible treatment options for underserved populations, addressing diseases that disproportionately impact low-income and middle-income countries.
This grant supports the enhancement of the C1 platform to enable rapid, cost-effective production of high-quality monoclonal antibodies. The goal is to improve global access to critical treatments and help address urgent global health challenges.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.